15893-47-7

Basic information

• Product Name: H-D-LEU-NH2
• Synonyms: H-D-LEU-NH2;D-LEUCINE AMIDE;D-LEUCINE-NH2;D-Leu-NH2
• CAS NO: 15893-47-7
• Molecular Formula: C₆H₁₄N₂O
• Molecular Weight: 130.19
• Mol File: 15893-47-7.mol
• Article Data: 24

Chemical Properties

• Melting Point: 235-237 °C
• Boiling Point: 250.9±23.0 °C(Predicted)
• Appearance: /
• Density: 0.980±0.06 g/cm3(Predicted)
• Storage Temp.: Store at 0°C
• PKA: 16.08±0.50(Predicted)
• CAS DataBase Reference: H-D-LEU-NH2(CAS DataBase Reference)
• NIST Chemistry Reference: H-D-LEU-NH2(15893-47-7)
• EPA Substance Registry System: H-D-LEU-NH2(15893-47-7)

Safety Data

• Hazardous Substances Data: 15893-47-7(Hazardous Substances Data)

Usage

General Description

H-D-LEU-NH2 is a chemical compound consisting of the amino acid leucine, which is a hydrophobic, aliphatic amino acid with a branched side chain. It is often found in proteins and is important for protein synthesis and muscle repair and growth. The H- at the beginning of the compound signifies that this is a peptide with a free amine group at the N-terminus, and the NH2 at the end signifies a free carboxylic acid group at the C-terminus. H-D-LEU-NH2 is commonly used in research and pharmaceuticals for its role in protein structure and function.

Upstream product

• 13079-20-4 2-Amino-4-methyl-pentanoic acid amide 
• 220184-57-6 (R)-2-(2-Methoxy-6-methyl-phenylamino)-4-methyl-pentanoic acid amide 
• 590-86-3 isovaleraldehyde 
• 329746-87-4 1-(2-hydroxy-6-methylphenyl)amino-3-methylbutane-1-carbonitrile 
• 220184-55-4 1-(2-hydroxy-6-methylphenyl)amino-3-methylbutane-1-carbonitrile 
• 80970-09-8 (R)-2-amino-4-methylpentanamide hydrochloride 
• 16937-99-8 N-Boc-D-Leu 
• 70543-81-6 (R)-tert-butyl (1-amino-4-methyl-1-oxopentan-2-yl)carbamate 
• 70533-96-9 N-tert-butoxycarbonyl-(L)-leucinamide 
• 61-90-5 L-leucine 
• 26400-33-9 N-(3-<2-furyl>acryloyl)-Gly-LeuNH2 
• 4801-79-0 N-benzyloxycarbonyl-L-leucinamide 
• 7517-19-3 methyl (L)-leucinate hydrochloride 
• 65356-77-6 N-acetyl-L-triptophanyl-L-leucine amide 

Downstream Products

• 70497-43-7 Carbobenzoxy-S-benzyl-cysteinyl-leucinamid-(L,L) 
• 17193-48-5 Z-(β-O-Bz-Asp)-Leu-NH2 
• 59937-71-2 (S)-4-Methyl-2-(2-nitro-phenylsulfanylamino)-pentanoic acid amide 
• 92489-58-2 N-CBZ-L-Tyr-D-LeuNH₂ 
• 132402-95-0 Mal-Tyr-D-Leu-NH₂ 
• 1161-13-3 N-Cbz-L-Phe 
• 13171-94-3 Z-Phe(D)LeuNH₂ 
• 159141-35-2 [(1S,2R)-1-Benzyl-2-((S)-1-carbamoyl-3-methyl-butylamino)-2-cyano-ethyl]-carbamic acid tert-butyl ester 
• 159247-02-6 [(1S,2S)-1-Benzyl-2-((S)-1-carbamoyl-3-methyl-butylamino)-2-cyano-ethyl]-carbamic acid tert-butyl ester 
• 95303-78-9 Z-L-Val-L-Leu-NH₂ 
• 17331-91-8 N-CBZ-L-Tyr-L-LeuNH₂ 
• 65118-58-3 N-Ac-L-Phe-L-Leu-NH₂ 
• 74257-73-1 tert-butyl ((S)-1-(((S)-1-amino-4-methyl-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate 
• 69193-13-1 Cbz-L-Phe-L-Leu-NH₂ 

Relevant articles and documents

Enzymatic stability of myostatin inhibitory 16-mer peptides

-

Bianthryl-based organocatalysts for the asymmetric Henry reaction of fluoroketones

We have developed a catalytic system based on bianthrylbis(thiourea) for the asymmetric Henry reaction of fluoroketones and nitroalkanes that resulted from the screening of a library containing 31 chiral non-racemic organocatalysts. The corresponding adducts were isolated in up to 6 times shorter reaction time in comparison with the previously published organocatalysts. High levels of stereocontrol have been generally observed, with measured product enantiomeric excesses up to 97% and diastereomeric ratio 3:2 (anti/syn). The above-mentioned catalysts have been successfully applied to the total asymmetric synthesis of CF3-tethered (S)-halostachines, which has proved that this method constitutes an easy entry to similar enantiopure compounds.

3, 5-disubstituted hydantoin compound as well as preparation method and application thereof

The invention provides a 3, 5-disubstituted hydantoin compound as well as a preparation method and an application thereof. The structure of the compound is shown in formula I in the description. The application of the 3, 5-disubstituted hydantoin compound shown in the formula I or solvates, hydrates or salts of the compound in preparation of medicines for treating Alzheimer's disease, vascular dementia and other dementia diseases with memory impairment also belongs to the protection scope. Animal experiments prove that the compound has the effect of saving memory of animal models, has high safety, does not have mutagenicity, can stay in blood for several hours after oral administration and intravenous injection, and can enter the brain.